Airsculpt Technologies Inc (AIRS) is at the forefront of the aesthetic medical technology sector, specializing in its proprietary AirSculpt® procedure, which sets a new standard for minimally invasive body contouring while prioritizing patient safety and comfort. The company is aggressively expanding its network of licensed practitioners and utilizing innovative technologies to solidify its competitive advantage in the rapidly growing non-invasive cosmetic treatment market. With rising global demand for aesthetic solutions, Airsculpt is well-positioned to capture market share and broaden its service offerings, driving robust growth and long-term value for its investors.
| Revenue (TTM) | $150.72M |
| Gross Profit (TTM) | $99.93M |
| EBITDA | $6.29M |
| Operating Margin | -0.07% |
| Return on Equity | -12.00% |
| Return on Assets | -1.91% |
| Revenue/Share (TTM) | $2.28 |
| Book Value | $1.47 |
| Price-to-Book | 1.13 |
| Price-to-Sales (TTM) | 0.69 |
| EV/Revenue | 1.127 |
| EV/EBITDA | 267.32 |
| Quarterly Earnings Growth (YoY) | 200.00% |
| Quarterly Revenue Growth (YoY) | -2.50% |
| Shares Outstanding | $72.09M |
| Float | $16.77M |
| % Insiders | 42.22% |
| % Institutions | 61.81% |
Volatility is currently expanding
AirSculpt Technologies NASDAQ: AIRS lowered its full-year revenue and profit outlook after third-quarter sales fell 8.7%, as fewer potential patients reached its website and several centers experienced operational problems.
TAMPA, Fla., Nov. 06, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced results for the third quarter ended September 30, 2026.
I rate AirSculpt Technologies a Speculative Buy with a $2.50 target, reflecting a 45% upside from current levels. AIRS's core procedure economics remain attractive, but profitability is pressured by elevated customer acquisition costs and underutilized infrastructure. The investment thesis hinges on AIRS improving marketing efficiency, increasing procedure volume, and securing refinancing without significant shareholder dilution.
MIAMI BEACH, Fla., Nov. 02, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt” or the “Company”) (NASDAQ: AIRS) an industry leader and provider of premium body contouring procedures, today announced it will report third quarter 2026 financial results before market open on Friday, November 6, 2026, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time.
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AirSculpt Technologies, Inc. ("AirSculpt" or the "Company") (NASDAQ: AIRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AirSculpt Technologies, Inc. (“AirSculpt” or the “Company”) (NASDAQ: AIRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AirSculpt Technologies, Inc. ("AirSculpt" or the "Company") (NASDAQ: AIRS).
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AirSculpt Technologies, Inc. ("AirSculpt" or the "Company") (NASDAQ: AIRS).
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AirSculpt Technologies, Inc. (“AirSculpt” or the “Company”) (NASDAQ: AIRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AirSculpt Technologies, Inc. ("AirSculpt" or the "Company") (NASDAQ: AIRS).
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AIRS and any ticker you trade — then tracks every position and per-strategy win rate.
